Alnylam has pushed back the data readout for its HELIOS-B trial from early 2024 to June/July 2024, causing a 10% decline in the stock price. The company has made changes to the study duration, primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback